To evaluate the effects of 50 mg mirabegron once daily for ureteric stent-related discomfort after ureteroscopic procedures by conducting a multicentre randomized study.
Introduction
Ureteric stents enable ureteric dilatation, divert urine flow to the bladder, and help in the recovery of ureteric injury; however, indwelling of ureteric stents causes discomfort and reduces quality of life (QoL) [1] . Joshi et al. [1] reported that >80% of patients experience stent-related pain, 58% report reduced work capacity, and 32% report sexual dysfunction. Ureteric stent-related discomfort has been attributed to a reduction in lower ureter and bladder spasms caused by local irritation by the stent [2] .
Many studies have indicated that agents such as antimuscarinics or a-1 adrenergic receptor antagonists (a-1 blockers) may improve stent-related symptoms. The indication to use an a-blocker is based on the similarity of stent-related symptoms to BPH-related LUTS, including urgency, frequency and suprapubic pain, which are caused by involuntary contraction [3, 4] . Similarly, antimuscarinic agents have been thought to block muscarinic receptors on the efferent neurons in the detrusor muscles and to reduce involuntary bladder contraction caused by trigone irritation, thus alleviating stent-induced overactive bladder (OAB) symptoms [5] ; however, the efficacy of these drugs is still controversial.
Mirabegron is the first and only b-3 adrenergic receptor agonist (b-3 agonist) currently available and approved for treatment of OAB symptoms [6] . As mentioned above, because stent-induced symptoms are similar to OAB symptoms, there is a theoretical advantage to using mirabegron to reduce bladder irritation symptoms or pain attributable to ureteric stents. To our knowledge, no studies have evaluated the efficacy of mirabegron for ureteric stent discomfort; thus, in the present randomized controlled trial (RCT), we evaluated the effects of mirabegron on improving symptoms and QoL in patients with indwelling ureteric stents using the validated Korean version of the Ureteral Stent Symptom Questionnaire (USSQ) [7] .
Materials and Methods

Study Design
This was a prospective, randomized, open-label, multicentre trial. After obtaining institutional review board approval from each institution, 100 patients were selected. The study design for the use of mirabegron for patients with a ureteric stone was approved by the Korean Ministry of Food and Drug Safety (approval number 20170118721, 25 May 2017). This study is registered at https://cris.nih.go.kr under registry number KCT0002599 (21 September 2017). The study was approved by the ethics board of the Korea University Ansan Hospital (No. 2017AS0042) and all patients provided written and informed consent. We strictly followed the 2010 CONSORT statement guidelines to design and report this trial [8] .
Study Participants
Eligible participants were adult patients (aged 19-80 years) who underwent unilateral retrograde rigid ureteroscopy (URS) or retrograde intrarenal surgery (RIRS) with planned ureteric stent insertion for urinary tract stones. The exclusion criteria were as follows: (i) concomitant use of a-blockers, anticholinergics, corticosteroids, calcium channel blockers, and analgesics; (ii) undergoing percutaneous nephrolithotomy, open ureteric surgery or laparoscopic ureteric surgery, including ureterolithotomy; (iii) neurogenic bladder, OAB syndrome, and neurological and psychiatric diseases; (iv) remnant ureteric stones after ureterolithotomy; (v) preoperative febrile UTI; (vi) pregnancy or breastfeeding; (vii) undergoing bilateral ureteroscopic surgery; (viii) a single kidney; (ix) moderate or severe cardiovascular or cerebrovascular disease; (x) hepatic dysfunction; (xi) history of pelvic surgery or irradiation; (xii) history of bladder or prostate surgery; (xiii) other acute medical conditions (including acute pancreatitis, acute gastroenteritis, musculoskeletal disorders) that might influence the USSQ pain score; and (xiv) preoperative indwelling of ureteric stent for relief of stone-related pain.
Intervention
Between May 2017 and February 2018, eligible patients were randomly and equally divided into a mirabegron 50 mg oncedaily group and a control (no medication) group. Information on the randomization process was protected and managed by the Korea University Ansan Hospital. Permuted-block random allocation with varying block sizes was performed. Sample size calculations were determined based on a previous meta-analysis investigating the effect of a-blockers in reducing ureteric stent-induced discomfort [9] . Assuming a similar treatment effect, a log-rank test with a two-sided significance level of 0.025 had an 80% power to detect differences between the groups, with a sample size of 45 in each group. After considering a maximum drop-out rate of 10%, 50 patients per group were randomized.
All patients provided written, informed consent and completed the IPSS questionnaire preoperatively. Unilateral ureteroscopic stone removal surgery was performed under general anaesthesia with a semi-rigid or flexible ureteroscope. After lithotripsy, the same type of 6-F ureteric catheter (Percuflex Plus; Boston Scientific, Natick, MA, USA) was used for all enrolled patients. During RIRS, the same diameter of ureteric access sheath was used (Navigator TM ; Boston Scientific). The length of the stent used was based on the height of each patient [10] . Patients in the case group received the study medication starting from the day after stent placement to the day of stent removal, while the control group received only the standardized discharge medication. For acute intractable pain after indwelling ureteric stent, the discharge medications were standardized for both groups as follows: 3 days of oral antibiotics (one tablet cefixime twice daily for 3 days, a total of six tablets) and oral NSAIDs (ibuprofen arginine 368.9 mg, one tablet twice daily for 3 days, a total of six tablets). If patients required further pain medication, they were asked to visit the medical centre for a prescription renewal (only ibuprofen arginine 368.9 mg, one tablet twice daily). In addition, patients were asked to maintain a diary recording analgesic usage amounts. The indwelling time of ureteric stent after surgery was standardized for 2 weeks, and the maximum indwelling time was not to exceed 20 days. We excluded patients who visited the hospital to remove the stent after 20 days, and classified them as follow-up loss. Patient follow-up was performed at week 2 (the day of stent removal) and week 3 (1 week after stent removal). Followup examinations were carried out on the day of stent removal. All patients completed the Korean version of the USSQ and the IPSS and reported a final analgesic usage amount. Seven days after stent removal, patients were evaluated by plain radiography and renal ultrasonography to confirm the removal of the stent, and post-void residual urine volume was measured.
The primary endpoints were USSQ body pain score and USSQ urinary symptom score. The secondary efficacy outcomes included scores in the other four domains of the USSQ (general health, work performance, sexual function, global QoL and oral analgesic requirements).
Statistical Analysis
Fisher's exact test was used to compare nominal variables, and the Mann-Whitney U-test was used to compare continuous variables between the two treatment arms before ureteric stenting. To compare outcomes after ureteric stent removal, chi-squared and non-parametric Wilcoxon twosample t-tests were used. Changes in IPSSs between the in situ stent (week 2) and preoperative time points were also compared between the groups. Continuous data are expressed as mean AE SD. Statistical analyses were performed using SPSS statistics version 21.0 (IBM Co., Armonk, NY, USA).
Results
Study Population
Between May 2017 and March 2018, a total of 100 patients from two medical institutions were randomly assigned to the treatment and control groups. Four patients were excluded from the final analysis because, for one patient, the surgical procedure was changed and three patients did not complete questionnaires because of follow-up loss. Finally, 48 patients remained in the mirabegron group and 48 patients in the control group. Overall a total of 96 treated patients were analysed. The CONSORT diagram of this study is shown in Fig. 1 . Baseline characteristics including body mass index, age, sex, stone size, stone location, stone position, duration of indwelling ureteric stent, and preoperative IPSS were similar between the two groups ( Table 1) . A total of 40 patients (83.3%) underwent URS in the control group and 34 patients (70.8%) underwent URS in the mirabegron group. Eight patients were treated with RIRS in the control group and 14 patients in the mirabegron group. There was no significant difference in the number of each procedure type between the two groups. Table 2 shows the results of postoperative USSQ symptom scores in both groups. The USSQ body pain score was 21.96 in the control group and 13.96 in the mirabegron group (P = 0.007). In addition, there were significant differences in the number of pain sites in each group (1.58 AE 1.37 vs 1.13 AE 0.89; P = 0.009) and in the overall pain score (5.58 AE 3.30 vs 2.83 AE 2.22; P = 0.002). The prevalence of flank pain (29.2% vs 12.5%; P = 0.038) and inguinal pain (29.2% vs 0%; P = 0.038) was lower in the mirabegron group than in the control group (Table S1) ; however, there were no significant differences in the prevalence of suprapubic pain and back pain between the two groups.
Primary and Secondary Endpoint
No significant differences in the total USSQ urinary symptom scores were observed between the two groups (32.58 AE 6.67 vs 27.92 AE 7.72; P = 0.582 [ Table 2 ]); however, among the USSQ urinary symptom scores, some subscores such as U5 (urge incontinence), U6 (sense of residual urine), U7 (dysuria), U9 (haematuria amount), U10 (total symptoms) and U11 (QoL related to the stent) were lower in the mirabegron group than in the control group (Table S1 ). Other subscores of the USSQ urinary symptoms score were not significantly different between the two groups. Likewise, there were no significant differences in the USSQ general health score (17.71 AE 5.52 vs 14.00 AE 5.16; P = 0.281) and the USSQ work performance score (7.25 AE 4.79 vs 6.17 AE 3.77; P = 0.221) between the two groups. In the USSQ sexual activity score relative to the proportion of stent-related sexual abstinence, the mirabegron group score was lower than that of the control group, but the difference was not statistically significant. The postoperative IPSS total score, voiding symptom score and storage symptom score were lower in the mirabegron group (Table 3 ). In addition, the change in IPSS storage symptom score was lower in the mirabegron group than in the control group (1.83 AE 4.39 vs 3.58 AE 3.58; P = 0.035). The change in IPSS total score and the voiding symptom subscore were also lower in the mirabegron group, but no significant differences were observed.
Complications
There were four drug-related complications (Table 2) . Diarrhoea was reported in two patients in the control group and in no patient in the mirabegron group. In addition, the number of patients who complained of constipation was two (4.2%) in the mirabegron group and one (2.1%) in the control group. One patient (2.1%) in the case group complained of dry mouth but no patient in the control group had this. In addition, none of the patients complained of adverse events such as acute urinary retention or tachycardia. There were no significant differences between the two groups (P = 0.227).
Discussion
Indwelling ureteric stents are associated with various types of discomfort and reduce the QoL of patients [1] . Joshi et al. [1] reported that~78% of patients with indwelling ureteric stents had urinary dysfunction symptoms and 80% patients had stent-related pain. The USSQ was developed to evaluate the discomfort associated with ureteric stents and it is currently widely used [11] . The exact mechanism involved in ureteric stent-associated discomfort is not yet known; however, many authors report that such discomfort is associated with ureteric spasms, urinary reflux attributable to ureteric stent, or trigonal irritation [12] . Different novel types of stents have been developed and evaluated to reduce stent-related discomfort; however, there is still controversy regarding their clinical application [13] . Conversely, pharmacological therapy, including analgesics, anticholinergics and a-blockers, remains the most effective option to manage stent-related symptoms. a-blockers have been shown to be effective according to a recent metaanalysis, in which it was determined that tamsulosin was the most effective [9, 14] . In addition, the results of many RCTs have shown that solifenacin and tolterodine are also effective in reducing stent-related discomfort [15] [16] [17] .
The role of a-blockers in reducing ureteric stent-related discomfort involves reduction of bladder outlet resistance to alleviate flank pain in male patients with preexisting BOO. It has been proposed that relaxing the distal ureter and irritation of the trigone decreases bladder outlet resistance and voiding pressure, thereby potentially decreasing the incidence of renal reflux and subsequent flank pain [4, 12, 18] . Otherwise, antimuscarinic agents may have an effect on involuntary contractions of the bladder induced by the distal end of ureteric stents, although with less convincing evidence [15, 19] .
The above-mentioned drugs, however, are not easy to apply to some patients with comorbidities because of the potential side effects. The most common medication-related complications of a-blockers are dizziness and orthostatic hypotension. Depending on the type of medication, medication-related adverse events are reported at a rate of 5% to 20% [20] . In addition, antimuscarinic agents have various adverse effects that decrease treatment compliance, such as dry mouth, constipation, blurred vision and dyspepsia [21] . To overcome these limitations, efforts to identify novel agents for the management of stent-associated discomfort has continued, and has led to our proposal of the b-3 agonist mirabegron. Mirabegron is an agonist of the b-3 adrenergic receptor, which is believed to be responsible for the relaxation of the detrusor smooth muscle during the storage phase [22] . Currently available agents help relax the detrusor smooth muscle, and result in increased bladder capacity without any changes in micturition pressure, post-void residual urine volume, or voiding contractions [23] . In addition, Nitti et al. [24] presented a phase III RCT in which the mirabegron tolerability profile was similar to that observed with placebo except for dry mouth, which occurred, on average, five times less frequently with mirabegron than with the tolterodine extended release 4 mg dose [24] .
Considering the function of mirabegron as a therapeutic agent for OAB, we assumed that mirabegron would be more effective for voiding symptoms attributable to stent-related discomfort, but unfortunately our results were not statistically significant. Specifically, frequency, nocturia and urgency scores in the USSQ urinary symptom subscore were not significantly decreased in the mirabegron group as compared with the control group. Similar results were noted in previous studies of solifenacin or peri-ureteric botulinum toxin injection in patients with ureteric stents [15, 25] . These results suggest that encouraging water intake for patients undergoing ureteroscope and ureteric stent indwelling may have had an effect and that the resulting polyuria reduced the response to the drug [15] .
Nevertheless, we observed a marked decrease in general stentrelated pain and some urinary symptoms. In addition, the change in the storage symptom score in the IPSS was significantly lower in the mirabegron group than in the control group. These findings support the potential effects of the b-3 agonist in ureteric stent-related symptoms. In addition, no specific adverse events were reported in the mirabegron group. Notably, we did not observe urinary retention in any of the patients treated with mirabegron. Possible explanations for these favourable results are described below.
First, as for tamsulosin, mirabegron may act via receptor activity on the ureter. Sigala et al. [26] presented gene expression analysis in which a-1d adrenergic receptor mRNA was expressed in all portions of the ureter, especially in the distal ureter [26] ; therefore, a-blockers have some degree of selectivity for the detrusor and the distal ureter, and have the potential to promote dilatation of the ureter and decrease pain. Moreover, Shen et al. [27] recently reported, based on a human ureter immunochemistry analysis, that all b-adrenergic receptor subtypes were expressed in the mucosa and muscular layers of the human ureter and that expression was downregulated in cases of ureter dilatation [27] . They demonstrated that the use of highly selective b-1 and b-3 agonists acting on ureteric smooth muscle lesions might help reduce the symptoms of ureteric smooth muscle spasm. The immunochemistry results from the above study can theoretically support the results of our clinical study.
Second, like antimuscarinic agents, mirabegron may act on involuntary contractions of bladder mediated by muscarinic receptors. In the largest phase III trial to date, the clinical efficacy of mirabegron was demonstrated relative to the treatment of symptoms of urgency, urinary incontinence and frequency [28] . This pharmacokinetic mechanism may improve urinary symptoms caused by a ureteric stent; however, there was no difference in USSQ urinary symptom score between the two groups in the present study. Nonetheless, mirabegron was found to be effective as shown by the IPSS storage symptom subscores and some urinary 870 © 2018 The Authors BJU International © 2018 BJU International symptom subscores (U6-residual urine sense, U7-dysuria, U10-total symptom, U11-stent-associated QoL) from the IPSS in patients with ureteric indwelling stents.
The present study has several limitations. Firstly, this was an open-label study. Because the study was conducted without any support from pharmaceutical companies, identical formulations and constellation of placebo effects could not be obtained. This design may have led to a potential bias, as neither the patient nor the physician were blinded to the treatments administered to each group. Control group participants therefore knew they were not being administered any therapeutic agent and were likely to have judged their condition to be worse than those who knew they were on active treatment. These limitations of the study design make the results difficult to interpret. Nevertheless, the body pain score (21.96 AE 9.81) and the urinary symptom score (32.58 AE 6.67) of the control group in our study were not significantly different from those of other RCTs with a placebo control group (USSQ body pain score, range 13.3-34.9; USSQ urinary symptom score, range 23-31.6) and the case group pain score (13.96 AE 7.24) in the present study was similar to the case group pain score in the same RCT (4.2-26.9) [9] . Secondly, we collected preoperative IPSS, but the preoperative USSQ scores were not collected for both groups. Comparative analysis of the changes in symptom score for both groups will further show the effects of ureteric stent and mirabegron on these patients. Finally, the ureteric stent indwelling time in the present study was longer than that of previous studies at~3-5 days. A previous study has shown that stent indwelling time may affect pain scores, therefore, the heterogenous indwelling times among the present and previous studies may have had some effect on USSQ scores [29] . The additional USSQ or IPSS assessments carried out in the early postoperative period may have compensated for these limitations.
Despite these limitations, the present study resulted in several important findings. First, to our knowledge, this study was the first to evaluate the impact of b-3 agonist therapy on ureteric stent-related discomfort after URS. The favourable outcome provides the first clinical evidence for future placebo-controlled studies or combination studies with other agents (e.g. a-blockers, antimuscarinic agents). Second, as mentioned above, because this study did not receive any support from pharmaceutical companies, the potential bias that could have occurred during the research and interpretation of the results was minimized [30] . Third, in this study, we suggest that alternative treatment options may be offered to patients who are burdened by treatment with a-blockers or antimuscarinic agents known to have a therapeutic effect. Finally, if a therapeutic effect by b-3 agonists in ureteric dilatation is validated by future studies, new treatment options for medical expulsion therapy may be considered.
In conclusion, overall, the present study indicates that the use of mirabegron once daily might help to reduce ureteric stentrelated discomfort. Larger-scale prospective double-blind RCTs or combination studies are warranted to evaluate the effects of mirabegron on ureteric stent-related symptoms.
